As reflected in the Form 10-Q for the quarter ended June 30, 2025 filed August 14, 2025, the Company reported stockholders’ equity in excess of $2.5 million and therefore satisfied the Equity Rule as ...

Portage, Michigan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host an Investor Day on Thursday, November 13, 2025, at 2:30 p.m. Eastern Time, in Mahwah, New Jersey.

Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, announced today that ...

Sol-Gel reported a net income of $11.6 million for the second quarter of 2025 and earnings of $4.17 per basic and diluted share, compared to a net loss of $1.9 million and earnings of $0.71 per basic ...

ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 ...

La Académie européenne d’allergologie et d’immunologie clinique (The European Academy of Allergy and Clinical Immunology, ...

Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue ...

The information contained herein is such as shall be made public by Aino Health AB (publ), in accordance with the EU Market Abuse Regulation. This information was made public, through the agency of ...

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells ...

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study ; Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid- ...

RxSight’s management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: ...

The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional ...